2. Search Result
Search Result
Results for "

anxiogenic

" in MedChemExpress (MCE) Product Catalog:

32

Inhibitors & Agonists

6

Peptides

2

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0203
    Atractylenolide III
    3 Publications Verification

    ICodonolactone; 8β-Hydroxyasterolide

    		 Apoptosis Neurological Disease Inflammation/Immunology Cancer
    Atractylenolide III (ICodonolactone) is the main component of Atractylodes rhizome and has the activity of inducing apoptosis in lung cancer cells. Atractylenolide III is an orally active gastroprotective agent .
    Atractylenolide III
  • HY-108403
    Phenibut

    β-Phenyl-GABA; 4-Amino-3-phenylbutanoic acid

    		 GABA Receptor Neurological Disease
    Phenibut (β-Phenyl-GABA) is a GABA-B agonist . Phenibut acts as a GABA-mimetic, primarily at GABAB receptors. Phenibut has anxiolytic and nootropic (cognition enhancing) effects .
    Phenibut
  • HY-W041333
    Phenibut hydrochloride

    β-Phenyl-GABA hydrochloride; 4-Amino-3-phenylbutanoic acid hydrochloride; 4-Amino-3-phenylbutyric acid hydrochloride

    		 GABA Receptor Neurological Disease
    Phenibut (β-Phenyl-GABA) hydrochloride is an orally active GABA-B agonist . Phenibut hydrochloride acts as a GABA-mimetic, primarily at GABAB?receptors. Phenibut hydrochloride has anxiolytic and nootropic (cognition enhancing) effects .
    Phenibut hydrochloride
  • HY-B0330B
    Levofloxacin hydrochloride
    Maximum Cited Publications
    36 Publications Verification

    (-)-Ofloxacin hydrochloride

    		 Antibiotic Bacterial DNA/RNA Synthesis Topoisomerase Orthopoxvirus Apoptosis Infection Neurological Disease Cancer
    Levofloxacin hydrochloride is an orally active antibiotic. Levofloxacin inhibits DNA gyrase and topoisomerase IV activity, inducing Apoptosis. Levofloxacin hydrochloride has antibacterial activity against both Gram-positive and Gram-negative bacteria. Levofloxacin hydrochloride exhibits anticancer activity against lung cancer. Levofloxacin hydrochloride has anti-acnegenic, anxiogenic, and analgesic effects. Levofloxacin hydrochloride shortens sleep duration in mice. Levofloxacin hydrochloride can be used in the research of infectious diseases (such as tuberculosis, chronic periodontitis, bacterial infections associated with stable COPD, and BK viremia) and lung cancer .
    Levofloxacin hydrochloride
  • HY-P1108
    Astressin 2B
    1 Publications Verification

    		 CRFR Neurological Disease Inflammation/Immunology
    Astressin 2B is a blood-brain barrier-impermeable, highly selective CRFR2 antagonist (rCRFR2, IC50=0.57 nM). Astressin 2B blocks the protective effects mediated by CRFR2, thereby exacerbating indomethacin (HY-14397)-induced hemorrhagic intestinal injury in rats. Astressin 2B reverses the protective effects of Urocortin 1 against intestinal hypermotility, bacterial invasion and upregulation of inflammatory mediators. Astressin 2B also blocks the anxiogenic effect of Urocortin 2 and attenuates stress-induced anxiety-related behaviors. In the Clostridioides difficile toxin A (C. difficile toxin A)-mediated enteritis model, Astressin 2B mimics the phenotype of CRFR2-deficient mice, significantly exacerbating intestinal epithelial damage, edema, neutrophil migration and the expression of multiple proinflammatory cytokines. Astressin 2B is an important tool molecule for investigating the intestinal protective mechanisms of CRFR2 .
    Astressin 2B
  • HY-P1108A
    Astressin 2B TFA
    1 Publications Verification

    		 CRFR Neurological Disease Inflammation/Immunology
    Astressin 2B TFA is a blood-brain barrier-impermeable, highly selective CRFR2 antagonist (rCRFR2, IC50=0.57 nM). Astressin 2B TFA blocks the protective effects mediated by CRFR2, thereby exacerbating indomethacin (HY-14397)-induced hemorrhagic intestinal injury in rats. Astressin 2B TFA reverses the protective effects of Urocortin 1 against intestinal hypermotility, bacterial invasion and upregulation of inflammatory mediators. Astressin 2B TFA also blocks the anxiogenic effect of Urocortin 2 and attenuates stress-induced anxiety-related behaviors. In the Clostridioides difficile toxin A (C. difficile toxin A)-mediated enteritis model, Astressin 2B TFA mimics the phenotype of CRFR2-deficient mice, significantly exacerbating intestinal epithelial damage, edema, neutrophil migration and the expression of multiple proinflammatory cytokines. Astressin 2B TFA is an important tool molecule for investigating the intestinal protective mechanisms of CRFR2 .
    Astressin 2B TFA
  • HY-P1294
    α-Helical CRF(9-41)

    		CRFR Neurological Disease
    α-Helical CRF(9-41) is a competitive CRF2 receptor antagonist with KB of ~100 nM. α-Helical CRF(9-41) is also a partial agonist of CRF1 receptor with an EC50 of 140 nM .
    α-Helical CRF(9-41)
  • HY-107726
    BIBP3226 TFA
    1 Publications Verification

    		 Neuropeptide Y Receptor Neurological Disease
    BIBP3226 TFA is a potent and selective neuropeptide Y Y1 (NPY Y1) and neuropeptide FF (NPFF) receptor antagonist, with Kis of 1.1, 79, and 108 nM for rNPY Y1, hNPFF2, and rNPFF, respectively. BIBP3226 TFA displays anxiogenic-like effect .
    BIBP3226 TFA
  • HY-16687A
    Eltoprazine hydrochloride

    DU 28853 hydrochloride

    		 5-HT Receptor Neurological Disease
    Eltoprazine (DU 28853) hydrochloride is a 5-HT1A/5-HT1B receptors agonist and a 5-HT2C receptor antagonist. Eltoprazine hydrochloride shows antiaggressive and anxiogenic effects .
    Eltoprazine hydrochloride
  • HY-121870
    Dimethocaine

    Larocaine

    		 Drug Derivative Cytochrome P450 Neurological Disease
    Dimethocaine (Larocaine) is a cocaine derivative and ester-type local anesthetic. Dimethocaine is metabolized by hP450 1A2, 2C19, 2D6, and 3A4 in vitro. Dimethocaine exhibits locomotor-promoting, reinforcing, and anxiogenic effects .
    Dimethocaine
  • HY-P1107A
    Antisauvagine-30 TFA
    4 Publications Verification

    aSvg-30 TFA

    		 CRFR Neurological Disease
    Antisauvagine-30 TFA (aSvg-30 TFA) is a potent, highly selective and competitive CRF2 receptor peptidic antagonist. Antisauvagine-30 TFA exhibits a Kd of 1.4 nM and 150 nM for mCRFR2β and CRFR1, respectively .
    Antisauvagine-30 TFA
  • HY-P1294A
    α-Helical CRF(9-41) TFA

    		CRFR Neurological Disease
    α-Helical CRF(9-41) TFA is a competitive CRF2 receptor antagonist with KB of ~100 nM. α-Helical CRF(9-41) TFA is also a partial agonist of CRF1 receptor with an EC50 of 140 nM .
    α-Helical CRF(9-41) TFA
  • HY-W009009
    L-838417

    		GABA Receptor Neurological Disease
    L-838417 is a selective partial agonist at the α2, α3 and α5 subtypes of the GABAA receptor and an antagonist at the α1, with binding Ki values of 0.79 nM, 0.67 nM, 1.67 nM, 267 nM, 2.25 nM and 2183 nM for α1β3γ2, α2β3γ2, α3β3γ2, α4β3γ2, α5β3γ2 and α6β3γ2. L-838417 has anti-anxiety activity .
    L-838417
  • HY-128174
    β-CCM

    Beta-CCM; Ro 22-7497

    		 GABA Receptor Neurological Disease
    β-CCM is a benzodiazepine receptor inverse agonist with anxiogenic and proconvulsant effects. β-CCM enhances emotional reactivity and reduces vulnerability to interference in spatial working memory tasks. β-CCM can be used for research on anxiety-related disorders .
    β-CCM
  • HY-16687
    Eltoprazine

    DU 28853

    		 5-HT Receptor Neurological Disease
    Eltoprazine (DU 28853) is a 5-HT1A/5-HT1B receptors agonist and a 5-HT2C receptor antagonist. Eltoprazine shows antiaggressive and anxiogenic effects .
    Eltoprazine
  • HY-N0203R
    Atractylenolide III (Standard)

    ICodonolactone (Standard); 8β-Hydroxyasterolide (Standard)

    		 Reference Standards Apoptosis Neurological Disease Inflammation/Immunology Cancer
    Atractylenolide III (Standard) is the analytical standard of Atractylenolide III. This product is intended for research and analytical applications. Atractylenolide III (ICodonolactone) is the main component of Atractylodes rhizome and has the activity of inducing apoptosis in lung cancer cells. Atractylenolide III is an orally active gastroprotective agent .
    Atractylenolide III (Standard)
  • HY-107726A
    BIBP3226

    		Neuropeptide Y Receptor Neurological Disease
    BIBP3226 is a potent and selective neuropeptide Y Y1 (NPY Y1) and neuropeptide FF (NPFF) receptor antagonist, with Kis of 1.1, 79, and 108 nM for rNPY Y1, hNPFF2, and rNPFF, respectively. BIBP3226 displays anxiogenic-like effect .
    BIBP3226
  • HY-P3684A
    [DPro5] Corticotropin Releasing Factor, human, rat TFA

    		CRFR Neurological Disease
    [DPro5] Corticotropin Releasing Factor, human, rat TFA is a selective corticotropin releasing factor/hormone R2 (CRH-R2)agonist. [DPro5] Corticotropin Releasing Factor, human, rat TFA fails to cause the typical anxiogenic effect, but modulates learning and memory processes in rat .
    [DPro5] Corticotropin Releasing Factor, human, rat TFA
  • HY-B0330BR
    Levofloxacin hydrochloride (Standard)

    (-)-Ofloxacin hydrochloride (Standard)

    		 Reference Standards Antibiotic Bacterial DNA/RNA Synthesis Topoisomerase Orthopoxvirus Apoptosis Infection Neurological Disease Cancer
    Levofloxacin (hydrochloride) (Standard) is the analytical standard of Levofloxacin hydrochloride (HY-B0330B). This product is intended for research and analytical applications. Levofloxacin hydrochloride is an orally active antibiotic. Levofloxacin inhibits DNA gyrase and topoisomerase IV activity, inducing Apoptosis. Levofloxacin hydrochloride has antibacterial activity against both Gram-positive and Gram-negative bacteria. Levofloxacin hydrochloride exhibits anticancer activity against lung cancer. Levofloxacin hydrochloride has anti-acnegenic, anxiogenic, and analgesic effects. Levofloxacin hydrochloride shortens sleep duration in mice. Levofloxacin hydrochloride can be used in the research of infectious diseases (such as tuberculosis, chronic periodontitis, bacterial infections associated with stable COPD, and BK viremia) and lung cancer .
    Levofloxacin hydrochloride (Standard)
  • HY-167238
    RS-30199

    		5-HT Receptor Neurological Disease
    RS-30199 is an anxiogenic agent. RS-30199 interacts with the 5-HT1A receptor. RS-30199 prolongs intromission latency. RS-30199 fully inhibits the facilitation of sexual behaviour caused by Delequamine (HY-106874) .
    RS-30199
  • HY-177509
    BBL454

    		Cholecystokinin Receptor Metabolic Disease
    BBL454 (Compound 43) is a Cholecystokinin 2B (CCK2B) receptor agonist. BBL454 induces hyperactivity and improves memory in rat models while it has weak activity on the peripheral CCK2 receptor and no anxiogenic activity. BBL454 increases gastric acid output in anesthetised rat models. BBL454 can be used for diabetes research .
    BBL454
  • HY-100924
    β-CCB

    		GABA Receptor Neurological Disease
    β-CCB is a ligand for benzodiazepine receptor, which inhibits the binding of [ 3H]flunitrazepam and ethyl (3-[ 3H]carboline-3-carboxylate to benzodiazepine receptors, with Ki of 3-4 nM. β-CCB exhibits proconvulsant and anxiogenic effects .
    β-CCB
  • HY-16687AR
    Eltoprazine hydrochloride (Standard)

    DU 28853 hydrochloride (Standard)

    		 5-HT Receptor Reference Standards Neurological Disease
    Eltoprazine (hydrochloride) (Standard) is the analytical standard of Eltoprazine (hydrochloride). This product is intended for research and analytical applications. Eltoprazine (DU 28853) hydrochloride is a 5-HT1A/5-HT1B receptors agonist and a 5-HT2C receptor antagonist. Eltoprazine hydrochloride shows antiaggressive and anxiogenic effects .
    Eltoprazine hydrochloride (Standard)
  • HY-W009009R
    L-838417 (Standard)

    		Reference Standards GABA Receptor Neurological Disease
    L-838417 (Standard) is the analytical standard of L-838417 (HY-W009009). This product is intended for research and analytical applications. L-838417 is a selective partial agonist at the α2, α3 and α5 subtypes of the GABAA receptor and an antagonist at the α1, with binding Ki values of 0.79 nM, 0.67 nM, 1.67 nM, 267 nM, 2.25 nM and 2183 nM for α1β3γ2, α2β3γ2, α3β3γ2, α4β3γ2, α5β3γ2 and α6β3γ2. L-838417 has anti-anxiety activity .
    L-838417 (Standard)
  • HY-16687B
    Eltoprazine dihydrochloride

    DU 28853 dihydrochloride

    		 5-HT Receptor Neurological Disease
    Eltoprazine (DU 28853) dihydrochloride is a 5-HT1A/5-HT1B receptors agonist and a 5-HT2C receptor antagonist. Eltoprazine dihydrochloride shows antiaggressive and anxiogenic effects .
    Eltoprazine dihydrochloride
  • HY-P3684
    [DPro5] Corticotropin Releasing Factor, human, rat

    		CRFR Endocrinology
    [DPro5] Corticotropin Releasing Factor, human, rat is a selective R2 agonist of corticotropin releasing factor/hormone. Corticotropin releasing factor (CRF) is a hypothalamic hormone, stimulates the release of adrenocorticotropic hormone (ACTH) and of β-endorphin. [DPro5] Corticotropin Releasing Factor, human, rat fails to cause the typical anxiogenic effect, but modulates learning and memory processes in rat .
    [DPro5] Corticotropin Releasing Factor, human, rat
  • HY-107719
    D-AP7

    		iGluR Neurological Disease
    D-AP7 is a specific NMDA receptor antagonist with inhibitory activity against epileptiform activity. D-AP7 attenuated neuronal activation in spot activity by reducing the duration and number of exogenously induced bursts. D-AP7 also increased the amplitude of secondary action potentials, which may restore neuronal activity in some epileptiform bursts. D-AP7 showed anxiogenic effects and impaired memory consolidation in passive avoidance learning .
    D-AP7
  • HY-153990
    FKBP51F67V-selective antagonist Ligand2

    		FKBP Neurological Disease
    FKBP51F67V-selective antagonist Ligand2 (example 3-3) is a potent FKBP51 F67V-selective antagonist ligand. FKBP51F67V-selective antagonist Ligand2 reverses the anxiogenic phenotype induced by overexpression of FKBP51 F67V in the amygdala. FKBP51F67V-selective antagonist Ligand2 binds to FKBP51 F67V, but not to wild-type FKBP51 or FKBP52 .
    FKBP51F67V-selective antagonist Ligand2
  • HY-108403R
    Phenibut (Standard)

    β-Phenyl-GABA (Standard); 4-Amino-3-phenylbutanoic acid (Standard)

    		 Reference Standards GABA Receptor Neurological Disease
    Phenibut (Standard) is the analytical standard of Phenibut (HY-108403). This product is intended for research and analytical applications. Phenibut (β-Phenyl-GABA) is a GABA-B agonist . Phenibut acts as a GABA-mimetic, primarily at GABAB receptors. Phenibut has anxiolytic and nootropic (cognition enhancing) effects .
    Phenibut (Standard)
  • HY-107726R
    BIBP3226 TFA (Standard)

    		Reference Standards Neuropeptide Y Receptor Neurological Disease
    BIBP3226 TFA (Standard) is the analytical standard of BIBP3226 (TFA) (HY-107726). This product is intended for research and analytical applications. BIBP3226 TFA is a potent and selective neuropeptide Y Y1 (NPY Y1) and neuropeptide FF (NPFF) receptor antagonist, with Kis of 1.1, 79, and 108 nM for rNPY Y1, hNPFF2, and rNPFF, respectively. BIBP3226 TFA displays anxiogenic-like effect .
    BIBP3226 TFA (Standard)
  • HY-183457A
    Cilobamine methanesulfonate

    		Monoamine Transporter Dopamine Transporter Cytochrome P450 Neurological Disease Metabolic Disease
    Cilobamine methanesulfonate is an orally active antidepressant and a dopamine/norepinephrine reuptake inhibitor. Cilobamine methanesulfonate increases the levels of Aniline hydroxylase and cytochrome P-450 in rat liver. Cilobamine methanesulfonate promotes hypertrophy of the smooth endoplasmic reticulum in rat liver hepatocytes, increases relative liver weight and recoverable microsomal protein. Cilobamine methanesulfonate produces stimulant and anxiogenic effects, and does not inhibit monoamine oxidase. Cilobamine methanesulfonate can be used in the research of depression .
    Cilobamine methanesulfonate
  • HY-15080
    GYKI 53405

    LY 293606

    		 iGluR Cardiovascular Disease Neurological Disease
    GYKI 53405 (LY 293606) is a non-competitive, orally active AMPA receptor antagonist. GYKI 53405 shows no significant binding affinity for GABAA, GABAB or benzodiazepine receptors. GYKI 53405 increases self-grooming behavior, induces wet dog-like shakes, reduces spontaneous activity, produces anxiolytic-like behavior, reverses the anxiogenic effect induced by mCPP, inhibits locomotor activity, suppresses sound-induced and maximal electroshock-induced seizures, prolongs survival in global cerebral ischemia models, and exhibits sustained anticonvulsant effects at doses below the sedation threshold. GYKI 53405 can be used in research related to absence epilepsy, anxiety disorders and global cerebral ischemia .
    GYKI 53405

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: